Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

It is with great pleasure that we present the latest edition of touchREVIEWS in Oncology & Haematology. This issue highlights the remarkable progress and innovation shaping the fields of oncology and haematology, featuring articles that delve into both emerging therapies and the evolving understanding of complex malignancies. We open with an editorial by Mohammad Ammad […]

Jonathan Rosenberg, ESMO 2022: Study EV-103 Cohort K – Enfortumab vedotin in combination with pembrolizumab in locally advanced or metastatic urothelial cancer

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 13th 2022

As there is a current need for effective and tolerable first line treatment options in patients with locally advanced or metastatic urothelial cancer (la/mUC), Dr Jonathan Rosenberg (Memorial Sloan Kettering Cancer Center, New York, NY, USA) joins touchONCOLOGY to discuss the positive results from Study EV-103 Cohort K. The study data supports ongoing investigations of first line enfortumab vedotin monotherapy or in combination with pembrolizumab in patients with la/mUC who have a high unmet need. Dr Rosenberg also highlights further clinical trial that are ongoing for the treatment of la/mUC.

The abstract entitled ‘Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)‘ Abstract LBA73, was presented at European Society for Medical Oncology (ESMO) 2022.

Questions:

  1. What are the major unmet needs in the first-line treatment of locally advanced or metastatic urothelial cancer? (0:13)
  2. What is the rationale for investigating the combination of enfortumab vedotin and pembrolizumab in this treatment setting? (1:08)
  3. What were the design and eligibility criteria of Study EV-103? (2:08)
  4. What were the efficacy and safety findings of the study? (3:03)
  5. What further investigations of this combined therapy are planned? (4:05)

Disclosures: Jonathan Rosenberg is a consultant for Astellas, Seagen, Gilead, and Merck; receives grant/research support from Astellas, and Seagen; is on the advisory board for Astellas, Seagen, Gilead, and Merck; and receives honoraria/honorarium from Pfizer, and EMD-Serono.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.

Filmed in coverage of ESMO 2022

Access more genitourinary cancer content here

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup